TAK-778

TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.

Product Specifications

CAS Number

[180185-61-9]

UNSPSC

12352005

Hazard Statement

H302

Target

Drug Derivative; IGF-1R; MMP; Phosphatase; TGF-β Receptor

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Others; Protein Tyrosine Kinase/RTK; TGF-beta/Smad

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TAK-778.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=CC=C(CP(OCC)(OCC)=O)C=C1)[C@@H](C2)S[C@@H](C)C(C3=C2C=C4OCOC4=C3)=O

Molecular Formula

C24H28NO7PS

Molecular Weight

505.52

Precautions

P264-P270-P330-P501

References & Citations

[1]Rosa AL, et al. TAK-778 enhances osteoblast differentiation of human bone marrow cells via an estrogen-receptor-dependent pathway. J Cell Biochem. 2004 Mar 1;91 (4) :749-55.|[2]Notoya K, et al. Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. J Pharmacol Exp Ther. 1999 Sep;290 (3) :1054-64.|[3]Cai M, et al. TAK-778 induces osteogenesis in ovariectomized rats via an estrogen receptor-dependent pathway. J Bone Miner Metab. 2011 Mar;29 (2) :168-73.